WAVEMAN · COMPANY

ANIK · Anika Therapeutics, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ANIK

Name: Anika Therapeutics, Inc. (ANIK) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Anika Therapeutics, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0000898437

CLUSTER · 3 INSIDERSC-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

$264.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-5.9%

XBRL, annual

NET MARGIN

-9.6%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$264.3K over 180 days

+$41.1K over 90 days

more than 87% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

69 funds added or opened last quarter

below 53% of Medical Devices

REVENUE

-5.9% year over year

below 81% of Medical Devices

MARGIN

-9.6% net margin

below 51% of Medical Devices

BUYBACKS

$9.5M repurchased, FY to 2026-06-30

below 65% of Medical Devices

SHORT

2.3% of shares outstanding short · 4.3 days to cover · settled 2026-07-31

below 58% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders bought a net $264.3K, but 1 Form 144 notice ($355.3K) are queued to sell.

69 funds added or opened positions in the latest 13F quarter, of 136 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +127.4%

+127.4%12M

INSIDER BUYFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $264.3K bought by insiders over 180 days, 69 funds added last quarter, $355.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Anika Therapeutics, Inc. insiders bought a net $264.3K of stock across 12 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Fischetti Gary P

Director

BUY

2026-08-04

1,000.0

$20.3K

Fischetti Gary P

Director

BUY

2026-08-03

1,000.0

$20.7K

HENNEMAN JOHN B III

Director

BUY

2026-05-01

5,000.0

$73.3K

Griffin Stephen D.

President and CEO

BUY

2026-04-30

12,200.0

$149.9K

Colleran David

EVP, General Counsel, Corp Sec

BUY

2022-05-11

1,500.0

$32.1K

12 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 7 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

1,449,671.0 sh

$21.2M

Caligan Partners LP

1,435,130.0 sh

$21.0M

MORGAN STANLEY

614,320.0 sh

$9.0M

VANGUARD CAPITAL MANAGEMENT LLC

572,113.0 sh

$8.4M

AQR CAPITAL MANAGEMENT LLC

559,846.0 sh

$8.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Jellison William R

FILED 2026-08-07

$355.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco NASDAQ Future Gen 200 ETF

$96.0K POSITION · AS OF 2026-02-28

0.7%

MFS Blended Research Small Cap Equity Portfolio

$189.0K POSITION · AS OF 2026-03-31

0.2%

MFS Blended Research Small Cap Equity Fund

$718.5K POSITION · AS OF 2026-02-28

0.2%

Royce Quant Small-Cap Quality Value ETF

$52.9K POSITION · AS OF 2026-03-31

0.2%

Ultra-Small Company Market Fund

$253.8K POSITION · AS OF 2026-03-31

0.2%

NVIT Small Cap Value Fund

$312.9K POSITION · AS OF 2026-03-31

0.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 12 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 3

0 ACTIVE

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$112.8M	$119.9M	$120.8M	$113.8M
GROSS PROFIT	$63.8M	$76.0M	$82.5M	$73.2M
OPERATING INCOME	$-11.1M	$-5.1M	$844.0K	$3.7M
NET INCOME	$-11.0M	$-56.0M	$-83.0M	$-15.0M
EPS (DILUTED)	-0.76	-3.83	-5.64	-1.02
OPERATING CASH FLOW	$11.2M	$5.4M	$-1.8M	$4.4M
CASH	$57.5M	$55.6M	$68.7M	$86.3M
BUYBACKS	$9.5M	$10.9M	$5.0M	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE